Logo image of RXST

RXSIGHT INC (RXST) Stock Fundamental Analysis

NASDAQ:RXST - Nasdaq - US78349D1072 - Common Stock - Currency: USD

29.6  -0.73 (-2.41%)

After market: 29.6 0 (0%)

Fundamental Rating

4

Overall RXST gets a fundamental rating of 4 out of 10. We evaluated RXST against 190 industry peers in the Health Care Equipment & Supplies industry. While RXST seems to be doing ok healthwise, there are quite some concerns on its profitability. RXST is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

RXST had negative earnings in the past year.
RXST had a negative operating cash flow in the past year.
In multiple years RXST reported negative net income over the last 5 years.
In the past 5 years RXST always reported negative operating cash flow.
RXST Yearly Net Income VS EBIT VS OCF VS FCFRXST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 0 20M -20M -40M -60M

1.2 Ratios

Looking at the Return On Assets, with a value of -9.89%, RXST is in the better half of the industry, outperforming 60.11% of the companies in the same industry.
RXST's Return On Equity of -11.07% is fine compared to the rest of the industry. RXST outperforms 64.36% of its industry peers.
Industry RankSector Rank
ROA -9.89%
ROE -11.07%
ROIC N/A
ROA(3y)-32.11%
ROA(5y)-13.87%
ROE(3y)-46.6%
ROE(5y)-4.03%
ROIC(3y)N/A
ROIC(5y)N/A
RXST Yearly ROA, ROE, ROICRXST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 50 -50 100

1.3 Margins

RXST has a better Gross Margin (68.44%) than 78.19% of its industry peers.
In the last couple of years the Gross Margin of RXST has grown nicely.
RXST does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.44%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y73.04%
GM growth 5YN/A
RXST Yearly Profit, Operating, Gross MarginsRXST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 1K -1K -2K

More info and screens

6

2. Health

2.1 Basic Checks

RXST does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for RXST has been increased compared to 1 year ago.
Compared to 1 year ago, RXST has an improved debt to assets ratio.
RXST Yearly Shares OutstandingRXST Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 10M 20M 30M
RXST Yearly Total Debt VS Total AssetsRXST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

An Altman-Z score of 20.32 indicates that RXST is not in any danger for bankruptcy at the moment.
RXST's Altman-Z score of 20.32 is amongst the best of the industry. RXST outperforms 95.21% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that RXST is not too dependend on debt financing.
RXST has a Debt to Equity ratio of 0.00. This is in the better half of the industry: RXST outperforms 68.62% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 20.32
ROIC/WACCN/A
WACC9.13%
RXST Yearly LT Debt VS Equity VS FCFRXST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 12.67 indicates that RXST has no problem at all paying its short term obligations.
RXST has a Current ratio of 12.67. This is amongst the best in the industry. RXST outperforms 96.81% of its industry peers.
RXST has a Quick Ratio of 11.71. This indicates that RXST is financially healthy and has no problem in meeting its short term obligations.
RXST has a better Quick ratio (11.71) than 96.28% of its industry peers.
Industry RankSector Rank
Current Ratio 12.67
Quick Ratio 11.71
RXST Yearly Current Assets VS Current LiabilitesRXST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

7

3. Growth

3.1 Past

RXST shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 50.60%, which is quite impressive.
Looking at the last year, RXST shows a very strong growth in Revenue. The Revenue has grown by 67.51%.
The Revenue has been growing by 82.40% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)50.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.39%
Revenue 1Y (TTM)67.51%
Revenue growth 3Y82.4%
Revenue growth 5YN/A
Sales Q2Q%59.08%

3.2 Future

RXST is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 30.68% yearly.
RXST is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 27.81% yearly.
EPS Next Y46.55%
EPS Next 2Y29.15%
EPS Next 3Y24.92%
EPS Next 5Y30.68%
Revenue Next Year58.78%
Revenue Next 2Y46.22%
Revenue Next 3Y37.98%
Revenue Next 5Y27.81%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
RXST Yearly Revenue VS EstimatesRXST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 100M 200M 300M
RXST Yearly EPS VS EstimatesRXST Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 1 -1 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RXST. In the last year negative earnings were reported.
Also next year RXST is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RXST Price Earnings VS Forward Price EarningsRXST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 -60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RXST Per share dataRXST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

A more expensive valuation may be justified as RXST's earnings are expected to grow with 24.92% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.15%
EPS Next 3Y24.92%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RXST!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RXSIGHT INC

NASDAQ:RXST (2/21/2025, 5:47:53 PM)

After market: 29.6 0 (0%)

29.6

-0.73 (-2.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)02-25 2025-02-25/amc
Inst Owners89.07%
Inst Owner Change1.37%
Ins Owners5.15%
Ins Owner Change-0.05%
Market Cap1.19B
Analysts83.75
Price Target53.14 (79.53%)
Short Float %6.07%
Short Ratio3.23
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)33.03%
Min EPS beat(2)29.76%
Max EPS beat(2)36.3%
EPS beat(4)4
Avg EPS beat(4)25.9%
Min EPS beat(4)7.94%
Max EPS beat(4)36.3%
EPS beat(8)8
Avg EPS beat(8)25.13%
EPS beat(12)12
Avg EPS beat(12)20.9%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)2.34%
Min Revenue beat(2)-1.26%
Max Revenue beat(2)5.95%
Revenue beat(4)3
Avg Revenue beat(4)2.57%
Min Revenue beat(4)-1.26%
Max Revenue beat(4)5.95%
Revenue beat(8)7
Avg Revenue beat(8)3.77%
Revenue beat(12)11
Avg Revenue beat(12)6.25%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-10.17%
PT rev (3m)-19.67%
EPS NQ rev (1m)1.08%
EPS NQ rev (3m)11.89%
EPS NY rev (1m)-0.23%
EPS NY rev (3m)14.02%
Revenue NQ rev (1m)0.05%
Revenue NQ rev (3m)0.09%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.07%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 9.3
P/FCF N/A
P/OCF N/A
P/B 4.3
P/tB 4.3
EV/EBITDA N/A
EPS(TTM)-0.83
EYN/A
EPS(NY)-0.46
Fwd EYN/A
FCF(TTM)-0.67
FCFYN/A
OCF(TTM)-0.52
OCFYN/A
SpS3.18
BVpS6.88
TBVpS6.88
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -9.89%
ROE -11.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.44%
FCFM N/A
ROA(3y)-32.11%
ROA(5y)-13.87%
ROE(3y)-46.6%
ROE(5y)-4.03%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y73.04%
GM growth 5YN/A
F-Score4
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 147.87%
Cap/Sales 4.82%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.67
Quick Ratio 11.71
Altman-Z 20.32
F-Score4
WACC9.13%
ROIC/WACCN/A
Cap/Depr(3y)73.84%
Cap/Depr(5y)77.79%
Cap/Sales(3y)6.29%
Cap/Sales(5y)43.75%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.39%
EPS Next Y46.55%
EPS Next 2Y29.15%
EPS Next 3Y24.92%
EPS Next 5Y30.68%
Revenue 1Y (TTM)67.51%
Revenue growth 3Y82.4%
Revenue growth 5YN/A
Sales Q2Q%59.08%
Revenue Next Year58.78%
Revenue Next 2Y46.22%
Revenue Next 3Y37.98%
Revenue Next 5Y27.81%
EBIT growth 1Y27.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year45.98%
EBIT Next 3Y30.5%
EBIT Next 5YN/A
FCF growth 1Y51.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y60.93%
OCF growth 3YN/A
OCF growth 5YN/A